Pregnancy News and Research

Latest Pregnancy News and Research

Many pregnant women in the U.S. have insufficient vitamin D levels: Study

Seven out of every ten pregnant women in the United States are not getting enough Vitamin D according to a study published in the May issue of the American Journal of Obstetrics and Gynecology. While prenatal vitamins do raise Vitamin D levels during pregnancy, the study shows that higher doses may be needed for many women.

12 May 2010

Preterm birth rates drop for most states and ethnic and gestational-age groups: March of Dimes

For the first time in three decades, the nation - and most states - saw a two-year decline in preterm birth rates, indicating that strategies implemented over the past seven years have begun to pay off, according to the March of Dimes.

12 May 2010

Health overhaul provisions raise moral, religious debates

The new health law has renewed concerns about some moral and religious issues, such as the government's role in providing sex education and health care workers' ability to opt out of providing end-of-life care and abortions.

12 May 2010

First Edition: May 11, 2010

Today's coverage includes more details regarding how the new health law moves forward with efforts to provide health insurance coverage to young adults.

11 May 2010

Potential new drug therapies for treatment of tuberculosis

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

11 May 2010

Pathway Genomics personal genetic testing kits to be sold at Walgreens

Pathway Genomics, a U.S.-based genetic testing company, today announced that Pathway's personal genetic testing kits will be available at Walgreens. Starting in mid-May the Pathway Genomics Insight™ Saliva Collection Kit will be sold at many of Walgreens' nearly 7,500 stores nationwide (with the exception of New York, due to a New York state law). The Insight™ Saliva Collection Kit will retail in the $20 to $30 price range.

11 May 2010

Personalized treatments for thyroid disorders to be presented at ATA meeting

Internationally recognized thyroid disease experts will meet to discuss "Thyroid Disorders in the Era of Personalized Medicine" May 13 - 16 in Minneapolis, Minnesota at the American Thyroid Association's (ATA) (www.thyroid.org) Spring Meeting to be held at the Minneapolis Hyatt Regency Hotel.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Pregnant women at risk for pregnancy problems caused by oral bacteria

Even healthy pregnant women can be at risk for pregnancy problems caused by oral bacteria. Researchers from Case Western Reserve University began to understand which bacteria from the 700 species living in the mouth are responsible for the growing health problem of preterm and stillbirths.

11 May 2010

Today's Opinions: The need for federal review of rate increases; Dems and GOP share blame for health costs; A phoney deal on Medicaid

This hodgepodge of controls over premiums needs to be backstopped by a national law that would allow the federal government to block unjustified rate increases where state officials lack the authority to do so. Attempts to include such powers in the newly enacted health care reform law failed (5/9).

10 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

50 years of the Contraceptive Pill

The Contraceptive Pill celebrated its 50th birthday on Mother's Day this year. The Pill was approved by the FDA in 1960 giving greater control to women about when they would like to give birth. The choice was supposed to help eliminate unwanted pregnancies and help couples grow closer. It was also supposed to help the couple financially by not placing burdens of early children on them.

9 May 2010

Researchers launch NIH-sponsored clinical trial for spinal deformity

Researchers at Northwestern Memorial have launched the first-ever National Institutes of Health-sponsored clinical trial for spinal deformity. The trial will evaluate the effectiveness of surgical and non-surgical treatments in people with adult scoliosis or curvature of the spine. Researchers also hope to identify important factors related to patient reported outcomes such as pain, activity and appearance.

7 May 2010

FHCO's second-quarter 2010 net revenues decrease 2% to $7.2 million

The Female Health Company, which manufactures and markets the FC2 Female Condom, today reported its operating results for the second quarter and first half of FY2010.

7 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.

7 May 2010